Dermatophytic Onychomycosis Therapeutic Market

Dermatophytic Onychomycosis Therapeutic Market Study by Distal Subungual Onychomycosis, White Superficial Onychomycosis, Proximal Subungual Onychomycosis, and Others from 2024 to 2034

Analysis of Dermatophytic Onychomycosis Therapeutic Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more

Dermatophytic Onychomycosis Therapeutic Market Outlook (2024 to 2034)

The global dermatophytic onychomycosis therapeutic market size is expected to be worth US$ 10,695.0 million by 2034, with a CAGR of 6.8% during the forecast period. The rising incidence of psoriasis and screening rates, awareness, and the expansion of the healthcare infrastructure are the main drivers of this growth, and the market is projected to reach US$ 5,520.5 million in 2024. The most prevalent nail illness, dermatophytic onychomycosis, which affects both fingernails and toenails, is expected to propel the therapeutic market between 2024 and 2034.

Key Market Growth Drivers

  • One-third of fungal infections worldwide are onychomycosis, a fungal nail infection that causes discoloration and thickness. As a result, there is a growing demand for dermatophytic onychomycosis therapy medications.
  • The increased prevalence of diabetes increases the risk of nail fungal infections. Studies show that onychomycosis risk increases with age and that the aging population is the main factor driving market growth.
  • Mycological visits, dermoscopy, and clinical investigations are required for onychomycosis, a common nail condition worldwide. Nevertheless, because fewer people visited the clinic, and as a result of clinic closures, the pandemic caused a fall in the market.
  • The market for medical materials is expected to grow due to the diagnosis of onychomycosis, which is made using a variety of tests such as potassium, oxygen, and hydrogen exams, cultures, and histological analyses of nail clippings and biopsies. Laser and photodynamic treatments are also used to treat the condition.

Potential pipeline candidates and the rising incidence of dermatophytic onychomycosis are projected to be the primary factors driving the growth of the worldwide market for treatments for the ailment. This growth is expected to strengthen the dermatophytic Onychomycosis Therapeutic Cure industry.

Report Attributes Details
Estimated Market Value (2024E) US$ 5,520.5 million
Forecasted Market Value (2034F) US$ 10,695.0 million
Global Market Growth Rate (2024 to 2034) 6.8% CAGR
Nail Paint Segment Growth Rate (2024 to 2034) 7.1%
Distal Subungual Onychomycosis Segment Growth Rate (2024 to 2034) 8.2%
North America Market Share (2024) 33.9%
Latin America Market Share (2024) 4.4%
Key Companies Profiled
  • Novartis AG
  • Moberg Pharma AB
  • Cardinal Health, Inc.
  • Pfizer Inc.
  • Almirall, S.A.
  • Bayer AG
  • Viatris Inc.
  • GlaxoSmithKline plc
  • Cipla Ltd.
  • Dr. Reddy’s Laboratories Ltd
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi S.A.
  • Medimetriks Pharmaceuticals, Inc.
  • Galderma
  • Johnson & Johnson

Don't Need a Global Report?

save 40%! on Country & Region specific reports

Which Factors Have Driven the Global Surge in Dermatophytic Onychomycosis Therapeutic Industry?

“Topical Solutions in Healthcare Infrastructure for Dermatophytic Onychomycosis Therapies”

The market for remedies to treat nail infections is anticipated to rise substantially during the projected period. This may be explained by the fact that people with toenail infections are increasingly choosing topical treatments. As more and more patients choose non-invasive, simple-to-apply treatment options, this trend will probably continue.

The rising incidence of onychomycosis, a fungal illness that is the most frequent cause of toenail infections, is another driver fueling the market's anticipated expansion. The market for treatments for nail infections is predicted to grow even more due to the increase in onychomycosis incidence.

Furthermore, during the forecast period, the increasing number of regulatory approvals for drugs used to treat toenail infections is expected to contribute to the market's growth significantly. This will probably result in the development of safer and more efficient treatment alternatives for those with toenail infections.

Generally, the market for solutions to treat nail infections is anticipated to develop significantly throughout the forecast period due to the growing number of regulatory approvals for pharmaceuticals, the increasing prevalence of onychomycosis, and the growing demand for topical treatment alternatives.

“Growing Rate of Dermatophytic Onychomycosis Fuels Market Expansion”

Several reasons are anticipated to contribute to the massive expansion of the dermatophytic onychomycosis medication market. The increasing incidence of onychomycosis, a disorder brought on by fungal infections of the nails, is one of the main factors contributing to this rise. Both fingernails and toenails may be impacted, although toenail onychomycosis is far more common.

The growing prevalence of dermatophyte-caused nail fungal diseases is a significant factor driving this market's expansion. The number of prescriptions written for treating dermatophytic onychomycosis has also significantly increased, which is anticipated to support market expansion.

The increasing rate of diabetes prevalence is another significant factor. The chance of getting a dermatophytic infection is higher in this long-term illness. The need for medications to treat dermatophytic onychomycosis is expected to rise as the number of people with diabetes continues to increase. During the projected years, these factors are anticipated to propel the dermatophytic onychomycosis medication market expansion.

Which Factors Present Challenges to the Dermatophytic Onychomycosis Therapeutic Market Growth?

“Lack of Awareness towards Toe Fungal Infection Treatment Thwarts Dermatophytic Onychomycosis Therapeutic Market Growth”

Hospitalization is more common in those with compromised immune systems, with around 30% of patients suffering from HIV infection and other immune-compromising diseases.

Treatment failure for dermatophytic onychomycosis is ascribed to variables, including noncompliance, misdiagnosis, and advanced illness. Recurrent infection is a danger because of several variables that raise the possibility of recurrence, even when the patient seems to recover.

Due to its lack of effectiveness and non-life-threatening nature, the therapy for dermatophytic onychomycosis has drawn criticism, which has made alternative medicines such as tea tree oil more competitive. Because of their significant adverse effects, current systemic therapy medications need to be monitored and evaluated for liver function.

The market's overall development is hampered by these issues together, which make it difficult for people with Dermatophytic Onychomycosis to receive appropriate therapy.

More Insights, Lesser Cost (-50% off)

Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR

Country-wise Insights

The primary driving force behind the research is the growing need for medications that lessen emuaidmax nail fungus in important foreign markets, such as the United States and Canada. It is anticipated that 90.5% of the United States industry is likely to be accounted for by finger nail fungal treatments by 2024. With a 46.5% market share, Brazil is predicted to lead the Latin American Dermatophytic Onychomycosis Therapeutic market by 2024.

Why is the United States Dominating the Global Dermatophytic Onychomycosis Therapeutic Market?

“Rise in Toe Fungal Infection Remedies Prospers in the United States”

The market for anti-fungal nail treatments is expected to expand significantly and reach a value of US$ 1,694 million by 2024 in the United States. Furthermore, a CAGR of 4.8% is estimated during the forecast period, culminating in a market value of US$ 2,696 million by 2034.

In the assessment period, the United States is expected to play a significant role in the development of the industry. This is due to the increasing efforts of players to study the disease, which has led to the domination of the regional market.

The industry's growth in the United States is mainly attributed to the increasing number of prescriptions for onychomycosis. Additionally, there has been a rise in research and demand for Jublia and Kerydin. These factors have contributed immensely to the development of the industry.

An additional element fueling the market's expansion is the rise in diabetes cases. One in ten Americans have diabetes, according to the CDC. The industry is anticipated to gain from these statistics during the projected period.

Which Factors Position Brazil in a Thriving Toe Fungus Medication Industry?

“Rising Prevalence of Toe Nail Fungus Medicine Drives Brazilian Healthcare Industry”

The market for dermachom nail fungus treatments in Brazil is anticipated to grow and reach a projected value of US$ 218 million by 2034. Brazil is expected to hold a substantial position of 46.5% of the Latin American Dermatophytic Onychomycosis Therapeutic market in 2024. The market has been growing steadily in recent years. The market is expected to increase at a 6.7% CAGR between 2024 and 2034.

Onychomycosis, or toenail fungus, is a common fungal ailment that impacts the toenails and fingernails. The onychomycosis treatment industry in Brazil is witnessing significant growth due to several factors. Firstly, the country has a rapidly increasing geriatric population, who are more prone to developing toenail fungus.

Onychomycosis is especially common in diabetic people, and as diabetes becomes more common in Brazil, there will be a greater need for onychomycosis treatments. Ultimately, Brazilians are becoming more conscious of the possible risks associated with onychomycosis, including the possibility of the illness spreading to other body areas. The need for onychomycosis therapy in Brazil is driven by all these reasons, which makes it a profitable market for pharmaceutical firms and healthcare professionals.

Category-wise Insights

Market forecasts from Fact.MR. Indicate that by 2024, the Nail Paint category will hold 64.6% of the market. Additionally, the Tablets category is anticipated to account for a sizeable 35.4% of the market, stabilizing and diversifying the industry's resources.

Additionally, by 2024, the Distal Subungual Onychomycosis segment is anticipated to account for 41.6% of the Dermatophytic Onychomycosis therapy market, contingent upon the indication. Furthermore, the worldwide market for emotional toenail fungus therapy is expected to have a significant 22.1% market share held by the Total Dystrophic Onychomycosis segment by 2034.

Why Is the Dermatophytic Onychomycosis Therapeutic Industry's Increased Demand for Nail Paints?

“Nail Paints Polishes the Unique Shade on the Dermatophytic Onychomycosis Therapeutic Industry”

Based on product type, Dermatophytic Onychomycosis Treatment is segmented into tablets and nail paints, according to recent market research conducted by Fact.MR, the nail paint industry, dominates the global market, holding a significant 64.6% market share by 2024. The demand for nail paint solutions for the emuaid nail fungus industry is also increasing, with an expected consumption value of US$ 3,564.9 million by 2024.

The nail paints category will continue dominating the market for the entire projection period. The market is expected to grow as topical nail lacquers become more popular than oral anti-fungal medications and Jublia usage increases. Nail paints can serve the dual purpose of providing cosmetic coverage to the affected nails while delivering therapeutic agents to treat the infection. This appeals to individuals who are conscious of the appearance of their nails and want to address both the cosmetic and restorative aspects simultaneously. Ongoing research and development may lead to the creation of more effective and aesthetically pleasing formulations of nail paints for onychomycosis treatment, further driving demand.

Know thy Competitors

Competitive landscape highlights only certain players
Complete list available upon request

Competitive Landscape

Major industry players are making significant investments in research and development to broaden their product offerings, which will raise demand for dermatologic onychomycosis treatments. Market participants engage in various strategic endeavors to expand their worldwide reach, including introducing new products, contractual arrangements, mergers and acquisitions, increased investment levels, and cooperation with other entities. To thrive in an increasingly cutthroat and dynamic market, the Dermatophytic Onychomycosis Treatment sector must provide affordable goods.

Major therapeutic product producers hope to increase demand for their goods globally and increase sales of their products for treating dermatophytic onychomycosis. To grow their market share and earnings, industry participants are concentrating on getting FDA clearance and working with regional distribution partners.

In the worldwide Dermatophytic Onychomycosis Treatment industry, manufacturers employ a crucial business strategy of manufacturing locally to lower operating costs, hence benefiting customers and expanding their market sector.

  • In December 2023, ADM Tronics stated that Origin Life Sciences, Inc., a client, would begin an IRB-approved pilot clinical research to assess the efficacy of their plasma-generated nitric oxide technology in treating onychomycosis.
  • In November 2023, Terbinafine, a new oral antifungal for onychomycosis treatment, was found to have higher cure rates, shorter treatment periods, and fewer adverse reactions.

Segmentation of Dermatophytic Onychomycosis Therapeutic Market

  • By Product:

    • Tablets
    • Nail Paint
  • By Indication:

    • Distal Subungual Onychomycosis
    • White Superficial Onychomycosis
    • Proximal Subungual Onychomycosis
    • Candidal Onychomycosis
    • Total Dystrophic Onychomycosis
  • By Age Group:

    • 0 to 18 Years
    • 18 to 39 Years
    • 40 to 64 Years
    • 65 Years & Above
  • By Distribution Channel:

    • Institutional Sales
    • Retail Sales
  • By Region:

    • North America
    • Europe
    • Latin America
    • East Asia
    • South Asia & Oceania
    • Middle East & Africa

- FAQs -

What was the value of the Dermatophytic Onychomycosis Therapeutic market in 2019?

The global Dermatophytic Onychomycosis Therapeutic market was worth US$ 4,278.3 million in 2019.

What is the sales outlook for Dermatophytic Onychomycosis Therapeutic in 2024?

The sales outlook for Dermatophytic Onychomycosis Therapeutic is likely to be valued at US$ 5,520.5 million in 2024.

What is the demand forecast for Dermatophytic Onychomycosis Therapeutic for the decade?

Demand for Dermatophytic Onychomycosis Therapeutic is projected to reach a market value of US$ 10,695.0 million by the end of 2034.

What is the adoption growth projection for Dermatophytic Onychomycosis Therapeutic?

Adoption of Dermatophytic Onychomycosis Therapeutic is projected to rise at a CAGR of 6.8% through 2034.

At what rate is the North American market in predicted to grow?

The North American market for Dermatophytic Onychomycosis Therapeutic is forecasted to expand at a CAGR of 4.8% through 2034.

Dermatophytic Onychomycosis Therapeutic Market

Schedule a Call